sublocade

SUBLOCADE significantly increased the rate of treatment success vs placebo (≥80% illicit opioid-free weeks) This graph shows that the treatment success rate was 28% among patients in the 300/100 mg group and 29% in the 300/300 mg group, vs 2% in the placebo group.

Sublocade is an injection that is given once a month. This means a single injection will last at least a month (28 to 30 days).

Results from long-term studies of buprenorphine extended-release injection (Sublocade) have shown that the treatment supported long-term abstinence from illicit opioid use and demonstrated a long-term safety profile consistent with that of transmucosal buprenorphine.

The RECOVER study reported that 75.3% of patients with moderate to severe opioid use disorder were abstinent from illicit opioids for a year after they completed 12 monthly buprenorphine extended-release injections. They all received medication from approved Sublocade providers.